The U.S. Centers for Disease Control and Prevention (CDC) recently issued a health alert to address a shortage of medication used to treat the respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants.
In a bulletin, the agency said there is currently a U.S.-wide “limited supply” of nirsevimab, which is described as a monoclonal antibody product that is recommended for preventing RSV in infants.
